Navigation Links
New Antibody for EGFR Causes Lung Cancer Regression

Mutant forms of the protein EGFR are important for the development of lung cancer in a substantial proportion of individuals with this disease. However, not all individuals// express the same mutant EGFR, for example, some have a mutation that affects the intracellular part of EGFR and some have a mutation that affects the extracellular part of EGFR (known as the EGFRvIII mutant).

The potential of therapeutics to benefit individuals with lung cancer caused by the distinct EGFR mutants can be examined using two mouse models of lung cancer, one driven by expression of EGFR with a mutation in the intracellular part of the protein and one driven by expression of the EGFRvIII mutant.

In a study, Kwok-Kin Wong and colleagues from the Dana-Farber Cancer Institute in Boston show that a mouse antibody that binds EGFR (mAb806) causes the regression of lung tumors in both models of lung cancer.

By contrast, a second antibody that binds EGFR (cetuximab), and that is already in clinical use for the treatment of a specific subset of patients with lung cancer, only induced tumor regression in mice with lung tumors driven by expression of EGFR with a mutation in the intracellular part of the protein.

Importantly, the humanized form of mAb806 (ch806) caused regression of lung tumors in both models of lung cancer. The data presented in this study therefore indicate that ch806 might provide a new therapeutic for the treatment of patients with lung cancer driven by mutant forms of EGFR, in particular the EGFRvIII mutant.

Source-Eurekalert
'"/>




Page: 1

Related medicine news :

1. Human Antibody That Can Block SARS
2. Therapeutic Monoclonal Antibody Production Is More Profitable Than Small Molecule Drugs
3. Cuba Registers New Antibody
4. Single Sugar Enables Antibody to Treat Inflammation
5. Monoclonal Antibody based system for Anthrax detection
6. Monoclonal Antibody Reduces Exacerbations in Asthmatics
7. Anti-rejection Therapy a Boon for Patients With "anti-donor" Antibody Levels
8. Antibody Therapy Prevents Type 1 Diabetes
9. J591- an Antibody Exclusively Targets Tumors
10. Breast Cancer Surgery Causes Psychological problems
11. Causes of weakness in the aged
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/12/2016)... ... ... According to an article published February 4th on mySA, robotically ... hernia repairs throughout the United States. Commenting on this article, Beverly Hills hernia repair ... has not only been expected, but it seems to be a natural result of ...
(Date:2/12/2016)... ... ... Enforcement Trends: , Back to the Future , Feb. 25, 2016 — 11:00 a.m. – ... who don’t learn from history are doomed to repeat it.” , An analysis of CDRH’s ... But that takes time. , Take a close look at the warning letters the ...
(Date:2/12/2016)... ... February 12, 2016 , ... T.E.N., ... have closed for the ISE Southeast Awards 2016. Finalists and winners of the ... ISE® Southeast Executive Forum and Awards Gala on March 15, 2016 at the ...
(Date:2/12/2016)... ... 12, 2016 , ... AssureVest Insurance Group, a locally owned insurance firm with ... will raise funds earmarked to purchase computers and software for Mrs. Harrison’s 2nd and ... is in a low-income area and has more than 60 2nd and 3rd graders ...
(Date:2/12/2016)... ... February 12, 2016 , ... Donor Network West, the organ procurement organization that ... partnership with San Ramon Regional Medical Center. Under the collaboration, the first of its ... to accommodate a more certain time frame for donor families for the recovery of ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... 12, 2016  SI-BONE, Inc., a medical device company that pioneered ... minimally invasive surgical (MIS) device indicated for fusion for certain disorders ... (NGS), the Medicare Administrative Contractor (MAC) covering the states of ... Maine , Massachusetts , Minnesota ... York , Rhode Island , ...
(Date:2/12/2016)... SAN DIEGO and SEOUL, ... -- Silicon Biosys­tems Menarini and Macrogen, Inc. today ... clinical assays and innovative procedures for precision medicine ... to combine Silicon Biosystems, DEPArray™ digital-sorting technology with ... development of tests certified under the Clinical Laboratory ...
(Date:2/12/2016)... , Feb. 12, 2016  Apellis Pharmaceuticals, ... a $47.1 million Series D preferred stock ... Management, Hillhouse Capital Group and venBio Global ... Investments, AJU IB Investment, and Epidarex Capital. The ... to further advance clinical trials in the ...
Breaking Medicine Technology: